Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
JACKSONVILLE, Fla., Feb. 9, 2017 /CNW/ -- TapImmune, Inc (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that the February 2nd presentation from Glynn Wilson, Chief Executive Officer and Dr. John Bonfiglio, Chief Operating Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
TapImmune, Inc's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
TapImmune Corporate Highlights
- Potential to be dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses
- Evaluating lead candidate in four Phase 2 studies, some with FDA Fast Track and Orphan Disease Status
- Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Dept. of Defense
- Compelling Phase 1 data show robust and enduring immune response against vaccine targets
- Multiple upcoming clinical value inflection points
Learn more about the event at www.VirtualInvestorConferences.com.
About TapImmune, Inc.
TapImmune Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate patients' killer T-cells and helper T-cells, or to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities, including immune checkpoint inhibitors.
Please visit the Company's website at www.tapimmune.com for more details.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE TapImmune, Inc.
For further information: TapImmune, Inc.:TapImmune Inc., Glynn Wilson, Ph.D., Chairman & CEO, (866) 359-7541, email@example.com; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org, http://tapimmune.com